IMMUNOCORRECTIVE EFFICIENCY OF ANTIHYPERTENSIVE PHARMACOTHERAPY IN COMBINATION WITH CYTOPROTECTOR IN PATIENTS WITH ARTERIAL HYPERTENSION

Chronic subclinical immune inflammation is one of the discussed mechanisms of target organ damage in arterial hypertension. The purpose of the study is to evaluate the immunocorrective efficacy of antihypertensive pharmacotherapy in patients with arterial hypertension alone and in combination with Mexican. The open, randomized controlled trial included 68 patients with a diagnosis of stage II hypertension, grade 2 arterial hypertension, left ventricular myocardial hypertrophy, risk 3. The concentration of cytokines (tumor necrosis factor, IL-1a, IL-6, IL-2, IL-8, IL-10, receptor antagonist IL-1), components of the complement system (C3, C4, C3a, C5, C5a, factor H and C1 inhibitor) and functional metabolic activity of peripheral blood neutrophils in patients with arterial hypertension against the background of the use of antihypertensive therapy (perindopril with amlodipine and perindopril with hypochlorothiazide) separately and in combination with mexicor. In patients with arterial hypertension, greater immunocorrective efficacy has been established in prescribing the combination of perindopril with amlodipino compared with the use of perindopril and hypochlorothiazide, while in both groups the additional administration of mexicor enhances this effect.